Our Commitment to Changing the Status Quo in Psoriasis Care

Psoriasis has a significant negative impact on quality of life (QoL), is linked to social stigmatisation, increased disability and decreased psychological well-being. Effective long-term management of psoriasis is essential for improving QoL and reducing the cumulative life course impairment.

The Epicensus is a UCB initiative that will challenge the status quo. This exciting pan-European integrated consensus programme was kicked-off in December 2020 and focuses on engagement, insight generation, multi-disciplinary conversation and consensus with key stakeholders dedicated to diagnosis, care, monitoring, access and patient-related outcomes in psoriasis. The Epicensus project engages stakeholders across three key groups (clinicians, payers and patient group representatives) across 8 European countries.

Following the insights questionnaire, the next stage has started which comprises a series of Delphi-surveys to define gaps and advance consensus on psoriasis care. The final phase is scheduled for early July 2021 when the consensus council will drive the development of a consensus manuscript to highlight where in the patient pathway, patients would benefit from an elevation in standard of care. Innovative roll-out activities will be explored at European country levels to disseminate the findings of this programme.

The ultimate goal is to drive action and initiate a paradigm shift on enhancing the delivery of the future of psoriasis care in Europe to optimise outcomes and finally allow our patients to live their lives to the full.